This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (8)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Immunization  • Bacterial Infections  • Alert me on articles by topic

Mike Mitka

JAMA. 2005;293:1433-1434.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The recent licensing of a new meningococcal conjugate vaccine has prompted government officials to expand recommended immunization practices. The new vaccine is expected to drastically reduce the prevalence of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135, which make up the majority of cases in the United States.

A new meningoccal vaccine is expected to markedly reduce the prevalence of invasive disease caused by Neisseria meningitidis. (Photo credit: www.sciencesource.com)

The Advisory Committee on Immunization Practices to the Centers for Disease Control and Prevention (CDC) recommended on February 10 that children aged 11 and 12 years, teens entering high school, and college freshman living in dormitories receive meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (Menactra). This vaccine, manufactured by Sanofi Pasteur (Swiftwater, Pa), received US Food and Drug Administration approval on January 14, 2005.

IMPROVED IMMUNITY

Menactra promises to . . . [Full Text of this Article]

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Update on Prevention of Meningococcal Disease: Focus on Tetravalent Meningococcal Conjugate Vaccine
Mehlhorn et al.
The Annals of Pharmacotherapy 2006;40:666-673.
ABSTRACT | FULL TEXT